Media Fills (Aseptic Process Simulation) Workflow

🧪

Media Fills - Simulating the Aseptic Process, Not the Product

Aseptic process simulation, commonly called a media fill, replaces the product with a microbiological growth medium and runs it through the complete filling process exactly as manufacturing would occur, including every intervention personnel would realistically perform. The purpose is to verify that the aseptic process itself, as executed by real personnel on the real line, reliably excludes microbial contamination. A media fill qualifies the process and the personnel performing it, not any single batch of product.

EU GMP Annex 1 2022 · FDA Aseptic Processing Guidance 2004 · PDA TR 22/28 · ISO 13408-1

EU GMP Annex 1 2022

FDA Aseptic Guidance 2004

PDA TR 22/28

ISO 13408-1

Unit Count / Batch Size

Fill volume representative of actual production batch size. FDA guidance references a minimum of approximately 5,000 units unless the production batch size is smaller.

Minimum: ~5,000 units (FDA)

Basis: Representative of batch size

Smaller batches: Match actual size

Run Duration

Simulation duration matches the longest actual production run time for the line, including all planned interventions and any realistic worst-case duration.

Basis: Longest actual run time

Includes: All planned interventions

Worst case: Maximum duration covered

Interventions

Both inherent (routine, expected) and corrective (non-routine, unplanned) interventions from the actual production process are represented during the simulation.

Inherent: Routine line activities

Corrective: Non-routine interventions

Basis: Actual production history

Frequency

Initial qualification requires three consecutive successful runs. Ongoing requalification is performed at least twice per year for each line, shift, and operator combination.

Initial: 3 consecutive successful runs

Ongoing: Twice yearly minimum

Scope: Per line, shift, operator

Phase 1

Design and Planning

1Define worst-case process conditions

Longest realistic run duration, maximum personnel present, and most challenging combination of interventions identified from actual production data to design a genuinely worst-case simulation.

FDA Aseptic Processing Guidance 2004

↓

2Select representative container-closure system and batch size

Container-closure combination and fill volume selected to represent, or bracket, the range of products actually run on the line.

PDA TR 22

↓

3Build the complete intervention list

Every inherent and corrective intervention performed on the line during actual production is catalogued and scheduled for inclusion in the simulation.

EU GMP Annex 1 2022

↓

4Schedule initial qualification or requalification

Initial line qualification requires three consecutive successful runs. Requalification scheduled at least twice yearly per line, shift, and operator combination thereafter.

EU GMP Annex 1 2022 · FDA Aseptic Processing Guidance 2004

Phase 2

Execution

5Set up the line under production-representative conditions

Line staffed and operated exactly as it would be during actual production, using qualified personnel in their normal gowning and working roles.

FDA Aseptic Processing Guidance 2004

↓

6Execute the simulated fill run with all interventions

Growth medium filled into containers exactly as product would be, with every planned intervention performed at the scheduled point in the run.

PDA TR 22

↓

7Conduct concurrent environmental and personnel monitoring

Full EM and personnel monitoring programme executed during the simulation exactly as it would be during production, providing correlation data for evaluation.

EU GMP Annex 1 2022

↓

Was the complete simulation executed per the approved protocol?

YES → Proceed to incubation NO → Deviation review, possible repeat

Phase 3

Incubation and Reading

8Incubate filled units per the validated regime

Units incubated across a dual-temperature regime, typically beginning at 20 to 25 degrees C followed by 30 to 35 degrees C, for a combined minimum of 14 days.

PDA TR 22

↓

9Perform interim and final visual inspections

Units inspected for turbidity indicating microbial growth at scheduled interim points and at the conclusion of the full incubation period.

PDA TR 22

↓

10Investigate any positive unit immediately

Any unit showing growth is immediately segregated and investigated, including organism identification, before the run's overall disposition is determined.

EU GMP Annex 1 2022

Phase 4

Evaluation and Requalification

11Calculate contamination rate against acceptance criteria

Number of contaminated units compared against the target of zero contamination and the defined investigation and rejection thresholds.

EU GMP Annex 1 2022 · FDA Aseptic Processing Guidance 2004

↓

12QA review with correlated EM and PM data

Quality unit reviews the complete media fill package together with environmental and personnel monitoring data from the same run before issuing final disposition.

21 CFR 211.22

↓

13Schedule the next requalification

Next routine requalification scheduled at the twice-yearly minimum, with additional trigger-based requalification following line changes, staffing changes, or extended shutdown.

EU GMP Annex 1 2022

Acceptance Criteria (EU GMP Annex 1 2022 / FDA Guidance)

Target: Zero Contamination

The target for every media fill is zero contaminated units. This is the goal the programme is designed around, not merely a numeric threshold to stay under.

EU GMP Annex 1 2022

One Contaminated Unit

A single contaminated unit triggers a documented investigation into probable cause, even though the run may not automatically fail depending on the investigation outcome.

FDA Aseptic Processing Guidance 2004

More Than One Contaminated Unit

More than one contaminated unit, or a pattern of recurring contamination, generally requires requalification of the line and personnel before resuming production.

EU GMP Annex 1 2022 · FDA Guidance

Positive Unit Investigation Response Steps

Step 1 - Segregate and secure the positive unit Isolate the affected unit and preserve all associated batch and monitoring records before further handling.

Step 2 - Identify the recovered organism Species-level identification helps correlate the finding against personnel, environmental, or facility-related sources.

Step 3 - Correlate against EM and personnel monitoring Cross-reference environmental and personnel monitoring data from the same run to identify a plausible source or contributing factor.

Step 4 - Review intervention records for the affected timeframe Examine which interventions were performed near the time the contaminated unit was filled, and by whom.

Step 5 - Determine root cause and corrective action Conclude a documented root cause and implement corrective action, with a successful requalification run required before resuming aseptic production.

Line Coverage Requirements

All filling positions represented Every filling head or nozzle position on multi-head lines represented in the unit distribution across the run.

Machine speed variation Simulation covers the range of machine speeds actually used in production, including any changeover between speeds if applicable.

Shift and operator coverage Requalification frequency structured so every shift and every qualified operator participates in simulations at the required frequency.

Container and closure format coverage Where a line runs multiple container or closure formats, the simulation programme covers the range or the worst-case format.

Worst-Case Design Requirements

Maximum Personnel Present Simulation includes the maximum number of personnel who would realistically be present in the classified area during actual production.

Maximum Duration Run duration matches or exceeds the longest actual production run, since fatigue and extended exposure time represent genuine contamination risk factors.

Aseptic Connections Every aseptic connection or disconnection performed during actual production is represented and performed by qualified personnel during the simulation.

Line Stoppages and Interruptions Realistic stoppages, such as equipment jams or planned breaks, are incorporated to represent genuine production interruption scenarios.

Container-Closure Worst Case Smallest or most challenging container-closure combination selected where multiple formats run on the same line, since smaller openings can represent greater contamination risk.

Filter and Equipment Simulation Sterilizing filter integrity testing and equipment setup steps performed identically to actual production, including any pre-use post-sterilization integrity test.

Lyophilization Simulation Where the process includes lyophilization, media-filled units undergo a representative simulated freeze-drying cycle before final incubation.

Growth Promotion Verification Media used in the simulation is confirmed capable of supporting growth of a panel of challenge organisms before and after the simulated fill.

Never do this

Design a simulation that represents only routine, best-case conditions. Reduce the intervention list to save time during execution. Skip growth promotion verification of the media before or after the run. Resume production after a failed media fill without completing a full investigation and successful requalification.

Media fill vs environmental monitoring

Environmental monitoring verifies the classified environment's ongoing state of control during actual production. A media fill verifies that the complete aseptic process, including personnel technique and interventions, reliably excludes contamination under simulated worst-case conditions.

Worst case vs typical case

A media fill designed around typical, best-case conditions provides limited assurance about actual production risk. The value of the simulation depends directly on how faithfully it represents the most challenging realistic conditions the line will encounter.

Key regulations

EU GMP Annex 1 2022 Section 9 - aseptic process simulation expectations. FDA Aseptic Processing Guidance 2004 - media fill design and acceptance criteria. PDA TR 22/28 - process simulation technical guidance. ISO 13408-1 - aseptic processing of health care products.